Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma

被引:19
作者
Shimizu, Katsuhiko [1 ]
Okita, Riki [1 ]
Saisho, Shinsuke [1 ]
Maeda, Ai [1 ]
Nojima, Yuji [1 ]
Nakata, Masao [1 ]
机构
[1] Kawasaki Med Sch, Dept Gen Thorac Surg, 577 Matsushima, Kurashiki, Okayama 7010192, Japan
关键词
non-small-cell lung cancer; tumor microenvironment; programmed cell death-1 ligand 1 (PD-L1); tumor-infiltrating CD8-positive T lymphocytes; cyclooxygenase-2 (Cox-2); CYCLOOXYGENASE-2; EXPRESSION; T-CELLS; CANCER REGISTRY; CHEMOTHERAPY; NIVOLUMAB; SURVIVAL; CLASSIFICATION; ASSOCIATION; RECURRENCE; DOCETAXEL;
D O I
10.2147/CMAR.S146897
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Programmed cell death-1 ligand 1 (PD-L1), tumor-infiltrating CD8-positive T lymphocytes (CD8-positive TILs), and cyclooxygenase-2 (Cox-2) have been used as prognostic tools in patients with lung adenocarcinoma. We conducted a retrospective review of data from 170 patients who had undergone pulmonary resection as an initial treatment for clinical T1-2 N0 lung adenocarcinoma. We then investigated the expressions of three biomarkers using immunohistochemical analyses and compared the expression levels with the clinicopathological characteristics and outcomes of the patients. Next, we classified the tumors into four groups based on the PD-L1 and CD8-positive TILs statuses and evaluated the prognostic significance of Cox-2 expression according to the tumor immune microenvironment classification. Tumors with positive PD-L1 expression levels had a significantly larger number of CD8-positive TILs than tumors with negative PD-L1 expression levels, whereas tumors with high Cox-2 expressions had significantly fewer CD8-positive TILs than tumors with low Cox-2 expressions. A multivariate analysis showed that histological subtype, nodal metastasis, CD8-positive TILs count, and PD-L1 expression were independent predictors of patient outcome. Using a classification based on the PD-L1 and CD8-positive TILs statuses, the outcomes of patients with a negative PD-L1 expression and a high CD8-positive TIL count were significantly better than those with other classifications. In patients with negative PD-L1 and low CD8-positive TILs, the rate of EGFR mutation was significantly higher than that in other classifications, and Cox-2 expression was a powerful predictor of outcome. Clinical and pathological features in conjunction with the tumor immune microenvironment classification indicate that lung adenocarcinoma should be divided into different subgroups for prognosis and treatment. Classification according to the PD-L1 and CD8-positive TILs statuses might enable the effects of Cox-2 inhibitor to be predicted.
引用
收藏
页码:741 / 750
页数:10
相关论文
共 36 条
[1]   Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients [J].
Ali, H. R. ;
Provenzano, E. ;
Dawson, S-J ;
Blows, F. M. ;
Liu, B. ;
Shah, M. ;
Earl, H. M. ;
Poole, C. J. ;
Hiller, L. ;
Dunn, J. A. ;
Bowden, S. J. ;
Twelves, C. ;
Bartlett, J. M. S. ;
Mahmoud, S. M. A. ;
Rakha, E. ;
Ellis, I. O. ;
Liu, S. ;
Gao, D. ;
Nielsen, T. O. ;
Pharoah, P. D. P. ;
Caldas, C. .
ANNALS OF ONCOLOGY, 2014, 25 (08) :1536-1543
[2]   A Japanese lung cancer registry study - Prognosis of 13,010 resected lung cancers [J].
Asamura, Hisao ;
Goya, Tomoyuki ;
Koshiishi, Yoshihiko ;
Sohara, Yasunori ;
Eguchi, Kenji ;
Mori, Masaki ;
Nakanishi, Yohichi ;
Tsuchiya, Ryosuke ;
Shimokata, Kaoru ;
Inoue, Hiroshi ;
Nitkiwa, Toshihiro ;
Miyaoka, Etsuo .
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (01) :46-52
[3]   Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy [J].
Blank, C ;
Gajewski, TF ;
Mackensen, A .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (04) :307-314
[4]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[5]   COX-2 expression positively correlates with PD-L1 expression in human melanoma cells [J].
Botti, Gerardo ;
Fratangelo, Federica ;
Cerrone, Margherita ;
Liguori, Giuseppina ;
Cantile, Monica ;
Anniciello, Anna Maria ;
Scala, Stefania ;
D'Alterio, Crescenzo ;
Trimarco, Chiara ;
Ianaro, Angela ;
Cirino, Giuseppe ;
Caraco, Corrado ;
Colombino, Maria ;
Palmieri, Giuseppe ;
Pepe, Stefano ;
Ascierto, Paolo Antonio ;
Sabbatino, Francesco ;
Scognamiglio, Giosue .
JOURNAL OF TRANSLATIONAL MEDICINE, 2017, 15
[6]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[7]   PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients [J].
D'Incecco, A. ;
Andreozzi, M. ;
Ludovini, V. ;
Rossi, E. ;
Capodanno, A. ;
Landi, L. ;
Tibaldi, C. ;
Minuti, G. ;
Salvini, J. ;
Coppi, E. ;
Chella, A. ;
Fontanini, G. ;
Filice, M. E. ;
Tornillo, L. ;
Incensati, R. M. ;
Sani, S. ;
Crino, L. ;
Terracciano, L. ;
Cappuzzo, F. .
BRITISH JOURNAL OF CANCER, 2015, 112 (01) :95-102
[8]   Stromal CD8+ T-cell Density-A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer [J].
Donnem, Tom ;
Hald, Sigurd M. ;
Paulsen, Erna-Elise ;
Richardsen, Elin ;
Al-Saad, Samer ;
Kilvaer, Thomas K. ;
Brustugun, Odd Terje ;
Helland, Aslaug ;
Lund-Iversen, Marius ;
Poehl, Mette ;
Olsen, Karen Ege ;
Ditzel, Henrik J. ;
Hansen, Olfred ;
Al-Shibli, Khalid ;
Kiselev, Yury ;
Sandanger, Torkjel M. ;
Andersen, Sigve ;
Pezzella, Francesco ;
Bremnes, Roy M. ;
Busund, Lill-Tove .
CLINICAL CANCER RESEARCH, 2015, 21 (11) :2635-2643
[9]   Cyclooxygenase in biology and disease [J].
Dubois, RN ;
Abramson, SB ;
Crofford, L ;
Gupta, RA ;
Simon, LS ;
Van De Putte, LBA ;
Lipsky, PE .
FASEB JOURNAL, 1998, 12 (12) :1063-1073
[10]   Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib plus chemotherapy - Cancer and leukemia group B trial 30203 [J].
Edelman, Martin J. ;
Watson, Dee ;
Wang, Xiaofei ;
Morrison, Carl ;
Kratzke, Robert A. ;
Jewell, Scott ;
Hodgson, Lydia ;
Mauer, Ann M. ;
Gajra, Ajeet ;
Masters, Gregory A. ;
Bedor, Michelle ;
Vokes, Everett E. ;
Green, Mark J. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) :848-855